Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

被引:96
作者
Sugiyama, Y [1 ]
Kato, Y [1 ]
Chu, XY [1 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
关键词
irinotecan; biliary excretion; P-glycoprotein; cMOAT;
D O I
10.1007/s002800051078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A frequent dose-limiting effect of irinotecan (CPT-11) is its gastrointestinal toxicity (diarrhea), which is thought to be related to biliary excretion of CPT-11 and its metabolites. Accordingly, we have investigated the mechanism of biliary excretion of these compounds. In vivo pharmacokinetic studies revealed that the biliary excretion of the four anionic forms of CPT-11 and its metabolites was reduced in Eisai hyperbilirubinemic rats, which carry a mutation of the hepatic canalicular multispecific organic anion transporter (cMOAT) gene. The protein encoded by this gene is expressed on the bile canalicular membrane and is responsible for the transport of organic anions into bile. Detailed analysis using isolated liver bile canalicular membrane vesicles to identify transport systems showed that cMOAT is responsible for biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN-38 glucuronide. The carboxylate form of SN-38 is transported by cMOAT alone. Transport of the high-affinity component of CPT-11 was inhibited by verapamil and PSC-833, but their effect on the transport of its low-affinity component was minimal. In addition, ATP dependence in the uptake of CPT-11 by membrane vesicles obtained from a P-glycoprotein (P-gp)-overexpressing cell line was observed. Thus P-gp may be responsible for transport of the high-affinity component of the carboxylate form of CPT-11.
引用
收藏
页码:S44 / S49
页数:6
相关论文
共 26 条
[21]   Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene [J].
Paulusma, CC ;
Bosma, PJ ;
Zaman, GJR ;
Bakker, CTM ;
Otter, M ;
Scheffer, GL ;
Scheper, RJ ;
Borst, P ;
Elferink, RPJO .
SCIENCE, 1996, 271 (5252) :1126-1128
[22]  
ROWINSKY EK, 1994, CANCER RES, V54, P427
[23]   PHARMACOLOGICAL CORRELATION BETWEEN TOTAL DRUG CONCENTRATION AND LACTONES OF CPT-11 AND SN-38 IN PATIENTS TREATED WITH CPT-11 [J].
SASAKI, Y ;
YOSHIDA, Y ;
SUDOH, K ;
HAKUSUI, H ;
FUJII, H ;
OHTSU, T ;
WAKITA, H ;
IGARASHI, T ;
ITOH, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (01) :111-116
[24]   PROTECTIVE EFFECTS OF KAMPO MEDICINES AND BAICALIN AGAINST INTESTINAL TOXICITY OF A NEW ANTICANCER CAMPTOTHECIN DERIVATIVE, IRINOTECAN HYDROCHLORIDE (CPT-11), IN RATS [J].
TAKASUNA, K ;
KASAI, Y ;
KITANO, Y ;
MORI, K ;
KOBAYASHI, R ;
HAGIWARA, T ;
KAKIHATA, K ;
HIROHASHI, M ;
NOMURA, M ;
NAGAI, E ;
KAMATAKI, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (10) :978-984
[25]   KINETIC-ANALYSIS OF HEPATOBILIARY TRANSPORT FOR CONJUGATED METABOLITES IN THE PERFUSED LIVER OF MUTANT RATS (EHBR) WITH HEREDITARY CONJUGATED HYPERBILIRUBINEMIA [J].
TAKENAKA, O ;
HORIE, T ;
KOBAYASHI, K ;
SUZUKI, H ;
SUGIYAMA, Y .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1746-1755
[26]   Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics [J].
Yamazaki, M ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 1996, 13 (04) :497-513